SCHEMBL7666332

SCHEMBL7666332

CNCC(CCO)c1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 6/20 0.47
SLC6A2 P23975 5/20 0.47
SLC6A3 Q01959 2/20 0.47
GABBR2 O75899 3/20 0.41
GABBR1 Q9UBS5 3/20 0.41
CYP2C9 P11712 3/20 0.41
LMNA P02545 2/20 0.41
BLM P54132 2/20 0.41
CYP3A4 P08684 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
NFKB1 P19838 1/20 0.41
DRD3 P35462 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
BRD4 O60885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5330393 0.84 SLC6A2 (0.40) SLC6A4SLC6A2SLC6A3CYP2C9BLM
SCHEMBL23149140 0.82 GABBR2 (0.46) GABBR2GABBR1CYP2C9LMNABLM
SCHEMBL5324521 0.82 SLC6A4 (0.42) SLC6A4SLC6A2SLC6A3GABBR2GABBR1
SCHEMBL5328294 0.82 SLC6A4 (0.42) SLC6A4SLC6A2SLC6A3GABBR2GABBR1
SCHEMBL5013017 0.82 SLC6A4 (0.47) SLC6A4SLC6A2SLC6A3CYP2C9BLM
SCHEMBL4872153 0.81 SLC6A2 (0.52) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6
SCHEMBL758733 0.81 SLC6A2 (0.52) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL8369503 0.80 SLC6A2 (0.51) SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6
SCHEMBL824927 0.79 GABBR2 (0.63) SLC6A4SLC6A2SLC6A3GABBR2GABBR1
SCHEMBL5362883 0.79 CYP3A4 (0.42) SLC6A4SLC6A2SLC6A3CYP2C9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403601-B1 TREATMENT OF ASTHMA, ANXIETY, DEPRESSION, EMESIS, URINARY INCONTINENCE AND RELATED CONDITIONS. ASTRAZENECA AB (SE) 2002-06-11 US disclosed
US-6365602-B1 FOR THERAPY OF DEPRESSION, ANXIETY, ASTHMA, PAIN, INFLAMMATION, URINARY INCONTINENCE AND OTHER DISEASE CONDITIONS ASTRA ZENECA AB (SE) 2002-04-02 US disclosed
EP-1137637-A1 N-(2-PHENYL-4-PIPERIDINYLBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS AstraZeneca AB (SE) 2001-10-04 EP disclosed
CN-1309638-A N-substituted naphthamides as neurokinin receptor antagonists ASTRAZENECA AB (SE) 2001-08-22 CN disclosed
EP-1097137-A1 N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS AstraZeneca AB (SE) 2001-05-09 EP disclosed
WO-2000034243-A1 N-(2-PHENYL-4-PIPERIDINYBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2000-06-15 WO disclosed
WO-2000002859-A1 N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2000-01-20 WO disclosed